AVEO Pharmaceuticals Inc (AVEO)

NASDAQ
8.670
+0.020(+0.23%)
  • Volume:
    113,741
  • Day's Range:
    8.670 - 8.990
  • 52 wk Range:
    3.060 - 9.370

AVEO Overview

Prev. Close
8.65
Day's Range
8.67-8.99
Revenue
61.3M
Open
8.69
52 wk Range
3.06-9.37
EPS
-1.05
Volume
113,741
Market Cap
299.41M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
301,488
P/E Ratio
-7.81
Beta
0.753
1-Year Change
37.96%
Shares Outstanding
34,614,284
Next Earnings Date
Nov 09, 2022
What is your sentiment on AVEO?
or
Vote to see community's results!

AVEO Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

AVEO Pharmaceuticals Inc Analysis

AVEO Pharmaceuticals Inc Company Profile

AVEO Pharmaceuticals Inc Company Profile

Employees
114

AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent’s Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyBuy
Technical IndicatorsSellStrong BuyStrong BuyStrong BuyStrong Buy
SummaryNeutralStrong BuyStrong BuyStrong BuyStrong Buy
  • How far is this going to tank???
    0
    • strong??
      0
      • Keep holding and buy lower to cost avg. 2020 will be big for this stock hitting new highs.
        0
        • I'm interested, tell me why do you think that?
          0
      • Unsure of when to sell. My avg is 0.84...1.00 maybe?
        1
        • yeah, I think Im gonna sell at 1, or just over.
          3
      • Holding on to this one...
        1
        • Holding on to this one...
          0
          • 1.00
            0
            • Mark, you think sell at a buck?
              0
            • if you're conservative yes , but if you got edge iw old say around 1.05 - 1.25
              0
            • *I*would
              0
          • is there a BO to JAZZ ongoing?16-19$
            0
            • 9340
              0
              • Is that your 4 digit pin?
                0